Status and phase
Conditions
Treatments
About
This is a prospective, single arm study, which is examining doxorubicin and cyclophosphamide (AC) once every 2 weeks with pegteograstim support in Korean early breast cancer.
Full description
Pegteograstim is a novel monoPEGylated recombinant human G-CSF. In this prospective study, the incidence of febrile neutropenia during four cycles of dose dense (DD) doxorubicin/cyclophosphamide (AC) with pegtoegrastim support is being investigated.
The primary objective of this study is to determine the incidence of febrile neutropenia during four cycles of DD AC with pegteograstim support (8 weeks).
Patients received four cycles of DD-AC (60 mg/m² doxorubicin and 600 mg/m² cyclophosphamide administered intravenously on day 1 every two weeks).
A fixed dose of 6.0 mg pegteograstim was administered subcutaneously on day 2 of each chemotherapy cycle (between 22 and 26 hours after the completion of chemotherapy).
Clinical, hematological, and biochemical assessments were done before the start of each cycle.
Adverse events (AEs) were graded using the National Cancer Institute Common Toxicity Criteria (NCI-CTCAE version 4.03).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Histological or cytological diagnosis of a primary breast cancer (stage I-III)
Age > 18 years of age and Age < 66 years of age
Eastern Cooperative Oncology Group (ECOG) performance status score 0 - 1
Patients who have plan to receive neoadjuvant or adjuvant dose-dense AC chemotherapy
Adequate organ functions
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
63 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal